Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HCID 2216생성일: 2026년 10월 26일
Apraclonidine
NC-14 · Aplonidine · Apraclonldine · APRACLONIDINE · 4-aminoclonidine · Apraclondine Hcl · Apraclonidine USP/EP/BP · Apraclonidine - API Standards
https://huagongshe.com/ko/chemical/2216
식별자 및 물리적 특성
| CAS No. | 66711-21-5 |
|---|
| 분자식 | C9H10Cl2N4 |
|---|
| 평균 분자량 | 245.11 g/mol |
|---|
| 단동위원소 질량 | 244.02825168 g/mol |
|---|
| SMILES | Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |
|---|
| InChIKey | IEJXVRYNEISIKR-UHFFFAOYSA-N |
|---|
| PubChem CID | 2216 |
|---|
| ChEMBL | CHEMBL647 |
|---|
| ChEBI | CHEBI:2788 |
|---|
| EC No. | 636-293-2 |
|---|
| DTXSID | DTXSID1048415 |
|---|
화학 및 물리적 성질
| XLogP | 1.3 |
|---|
| 극성 표면적 | 62.4 |
|---|
| 수소 결합 공여자 수 | 3 |
|---|
| 수소 결합 수용자 수 | 2 |
|---|
| 회전 가능 결합 수 | 2 |
|---|
| 무거운 원자 수 | 15 |
|---|
| 형식 전하 | 0 |
|---|
| 복잡도 | 246 |
|---|
| 의약품 | Pharmaceuticals -> Listed in ZINC15 |
|---|
| LogP(분배 계수) | 1.4 |
|---|
| 용해도 | 4.09e-01 g/L45%(w/v) aq 2-하이드록시프로필--사이클로덱스트린: 1.4mg/mL 용액은 4℃에서 며칠 동안 보관할 수 있습니다. |
|---|
| Human Drugs | Breast FeedingLactationAdrenergic alpha-2 Receptor AgonistsAntiglaucoma Agents |
|---|
| Physical Description | Solid |
|---|
| 녹는점 | >230° |
|---|
| 끓는 점 | 395.5±52.0 °C(Predicted) |
|---|
| 밀도 | 1.63±0.1 g/cm3(Predicted) |
|---|
| 저장 조건 | Sealed in dry,2-8°C |
|---|
| pKa(산도 계수) | 9.26±0.50(Predicted) |
|---|
| 물리적 상태 | 고체 |
|---|
| 색상 | 하얀색 |
|---|
안전 및 규제
| GHS 분류 | DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P261, P262, P264, P270, P271, P280, P301+P316, P302+P352, P304+P340, P316, P321, P330, P361+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|
| Hazard Classes and Categories | Acute Tox. 3 (100%) |
|---|
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
|---|
| 수질 위해 등급(WGK) | 3 |
|---|
| 운송 번호(UN) | UN 2811 6.1/PG 1 |
|---|
| 위험 문구(R) | 23/24/25 |
|---|
| 위험 표시 | T |
|---|
| 안전 문구(S) | 22-36/37/39-45 |
|---|
용도
일반 설명
In addition to its therapeutic use as an antihypertensiveagent, clonidine has been found to provide beneficialeffects in several other situations, including glaucoma,spasticity, migraine prophylaxis, opiate withdrawal syndrome,and anesthesia. This has prompted the developmentof analogs of clonidine for specific use in some of the mentionedareas. Two of such examples are apraclonidine andbrimonidine. Apraclonidine does not cross the BBB.However, brimonidine can cross the BBB and hence canproduce hypotension and sedation, although these CNSeffects are slight compared with those of clonidine. CNS effectsof these drugs are correlated well to their log P, pKa,and thus log D value. Both apraclonidine and brimonidineare selective α2-agonists with α1: α2 ratios of 30:1 and1,000:1, respectively. Brimonidine is a much more selectiveα2-agonist than clonidine or apraclonidine and is a firstlineagent for treating glaucoma. Apraclonidines’s primarymechanism of action may be related to a reduction of aqueousformation, whereas brimonidine lowers intraocularpressure by reducing aqueous humor production and increasinguveoscleral outflow. Apraclonidine is used specificallyto control elevations in intraocular pressure that canoccur during laser surgery on the eye. Another example istizanidine (Zanaflex), which finds use in treating spasticityassociated with multiple sclerosis or spinal cord injury. Bystimulating 2-adrenergic receptors, it is believed to decreasethe release of excitatory amino acid NTs from spinalcord interneurons.